Cargando…

Using strategic price negotiations to contain costs and expand access to medicines in China

Detalles Bibliográficos
Autores principales:	Si, Lei, Xu, Lizheng, Chen, Mingsheng, Jan, Stephen
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BMJ Publishing Group 2020
Materias:	Commentary
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7042576/ https://www.ncbi.nlm.nih.gov/pubmed/32133184 http://dx.doi.org/10.1136/bmjgh-2019-002256

Ejemplares similares

Prices and Clinical Benefit of National Price-Negotiated Anticancer Medicines in China
por: Zhang, Yichen, et al.
Publicado: (2022)

Health technology assessment-informed pricing negotiation in China: higher negotiated price for more effective targeted anticancer medicines?
por: Huang, Cong, et al.
Publicado: (2022)

Strategic negotiation /
por: Kennedy, Gavin
Publicado: (2007)

Promoting Access to Innovative Anticancer Medicines: A Review of Drug Price and National Reimbursement Negotiation in China
por: Mingge, Xia, et al.
Publicado: (2023)

Impact of the national drug price negotiation policy on the utilization, cost, and accessibility of anticancer medicines in China: A controlled interrupted time series study
por: Cai, Lele, et al.
Publicado: (2022)

The correlation between the costs and clinical benefits of national price-negotiated anticancer drugs for specific cancers in China
por: Bao, Yuwen, et al.
Publicado: (2023)

Negotiating prices of drugs for rare diseases
por: Henrard, Séverine, et al.
Publicado: (2016)

Payer-Negotiated Prices for Telemedicine Services
por: Wu, Shannon S., et al.
Publicado: (2022)

Vaccine pricing strategies in China
por: Zhang, Haonan, et al.
Publicado: (2023)

Costs and assessment in medical education: a strategic view
por: Walsh, Kieran
Publicado: (2016)

Consumption and cost trends of EGFR TKIs: influences of reimbursement and national price negotiation
por: Wu, Di, et al.
Publicado: (2022)

Access to high cost medicines in Australia: ethical perspectives
por: Lu, Christine Y, et al.
Publicado: (2008)

Predictors of negotiated prices for new drugs in Germany
por: Gandjour, Afschin, et al.
Publicado: (2020)

Access to the 340B Drug Pricing Program: is there evidence of strategic hospital behavior?
por: Mulligan, Karen, et al.
Publicado: (2021)

A Critical Examination of Simulation Pricing and Access Recommendations for Atopic Dermatitis
por: Langley, Paul C.
Publicado: (2021)

Comparison of US Hospital Cash Prices and Commercial Negotiated Prices for 70 Services
por: Jiang, John (Xuefeng), et al.
Publicado: (2021)

The impacts of government reimbursement negotiation on targeted anticancer medication price, volume and spending in China
por: Zhang, Yichen, et al.
Publicado: (2021)

A new strategic phase for genomic medicine in UK health services
por: Burton, Hilary, et al.
Publicado: (2009)

Strategic corporate negotiations: a framework for win-win agreements
por: Caputo, Andrea
Publicado: (2019)

The Rising Cost of Insulin for Pump Users: How Policy Drives Prices
por: Brown-Georgi, Julia, et al.
Publicado: (2020)

Strategic Mental Health Planning and its Practice in China: Retrospect and Prospect
por: XIE, Bin
Publicado: (2017)

Relationship between financial speculation and food prices or price volatility: applying the principles of evidence-based medicine to current debates in Germany
por: Bozorgmehr, Kayvan, et al.
Publicado: (2013)

Smith’s paradox of price and negotiation: Empirical evidence from India
por: Dey Biswas, Sattwick
Publicado: (2021)

Access to Paediatric Essential Medicines: A Survey of Prices, Availability, Affordability and Price Components in Shaanxi Province, China
por: Wang, Xiao, et al.
Publicado: (2014)

The State of Climate Negotiations: a personal scientific commentary
por: Archer, David E
Publicado: (2013)

Price-Transparency and Cost Accounting: Challenges for Health Care Organizations in the Consumer-Driven Era
por: Hilsenrath, Peter, et al.
Publicado: (2015)

Trends in accessibility of negotiated targeted anti-cancer medicines in Nanjing, China: An interrupted time series analysis
por: Liu, Yanyan, et al.
Publicado: (2022)

Price Matters – Relevance of Strategic Pricing for Swiss Tourism in the Past, Present and Future
por: Bandi, Monika, et al.
Publicado: (2014)

What Is the Price Benchmark to Replace Average Wholesale Price (AWP)?
por: Curtiss, Frederic R.
Publicado: (2010)

Affordable Prices Without Threatening the Oncological R&D Pipeline—An Economic Experiment on Transparency in Price Negotiations
por: Franzen, Nora, et al.
Publicado: (2022)

Liberalizing abortion to reduce maternal mortality: expanding access to all Ethiopians
por: Feyssa, Mekdes Daba, et al.
Publicado: (2022)

Strategic procurement and international collaboration to improve access to medicines
por: Ferrario, Alessandra, et al.
Publicado: (2017)

For Whom the Price Escalates: High Price and Uncertain Value of Cancer Drugs
por: Shin, Gyeongseon, et al.
Publicado: (2022)

Strategic Ambiguity: How Pre-Tenure Faculty Negotiate the Hidden Rules of Academia
por: Cate, Leandra, et al.
Publicado: (2022)

Negotiating with Backbone: Eight Sales Strategies to Defend Your Price and Value
por: Holden, Reed
Publicado: (2012)

Negotiating with Backbone: Eight Sales Strategies to Defend Your Price and Value
por: Holden, Reed
Publicado: (2015)

Measuring Access to Medicines: A Survey of Prices, Availability and Affordability in Shaanxi Province of China
por: Jiang, Minghuan, et al.
Publicado: (2013)

Forming a medicines pricing policy for low and middle-income countries (LMICs): the case for Pakistan
por: Babar, Zaheer-Ud-Din
Publicado: (2022)

Open access and medicinal chemistry
por: Swain, Chris
Publicado: (2007)

Strategic information is everyone’s business: perspectives from an international stakeholder meeting to enhance strategic information data along the HIV Cascade for people who inject drugs
por: Pierce, Richard D., et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_e0kfvch8ndorjqqopufp040dd5